Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


OxyPharma adds clinics for its Rabeximod study


[Stockholm, Sweden, June 20, 2008.] Swedish drug development company OxyPharma has added clinics in two more countries to increase enrollment in its phase II clinical trial of Rabeximod, an orally administered compound for treatment of moderate or severe active Rheumatoid Arthritis (RA).

OxyPharma has received regulatory clearance to start enrollment of patients in clinics in Poland and Georgia, which brings the number of participating countries to nine. The company has also increased the number of clinics in some of the existing countries - Belgium, Bulgaria, Latvia, Lithuania, Romania, Serbia, and the UK. The objective is to increase enrollment and speed up the study. At present, approximately one third of the required number of patients (224) has started treatment.

OxyPharma's phase II trial of its immunomodulator, Rabeximod, is carried out in patients with moderate to severe active RA. The phase II study is done by Pharm-Olam International, a multi-national contract research organization. Principal Investigator is Prof. Lars Klareskog, Head of Rheumatology Unit at Karolinska Hospital, Stockholm, Sweden.

OxyPharma's primary objective is to evaluate the clinical response rate of Rabeximod when added to a stable dose of methotrexate in 224 patients with moderate or severe active RA. Rabeximod is given orally once daily for 12 weeks.

About OxyPharma:

OxyPharma is a Swedish drug development company developing new drugs primarily for the treatment of Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). The development programs are carried out in collaboration with the Karolinska Institute in Stockholm, Sweden and contract research organizations (CRO's) in England, Sweden and Israel.

OxyPharma was founded in 2002 and is based in Stockholm, Sweden. The company's largest shareholder is innovator and entrepreneur Leif Lundblad (mainly through his investment company LLD Nybohov Invest). Ulf Björklund is OxyPharma's CEO.


For additional information please contact:

Ulf Björklund
CEO, OxyPharma AB
Phone: +46 8 726 17 02 or +46 70 667 04 40

Email: ulf.bjorklund@oxypharma.com

or

Peter Karaszi
Press Officer, OxyPharma AB
Phone: +46 70 341 46 53

Email: peter.karaszi@oxypharma.com

Also see our web site: www.oxypharma.com

OxyPharma is a member of SwedenBIO. For more information about Swedish biotech, please visit www.swedenbio.com


Publisher Contact Information:

OxyPharma AB
+46 8 726 17 02
ulf.bjorklund@oxypharma.com

Company profile of OxyPharma AB
Past press releases of OxyPharma AB.

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.